ERBB2 and gastroesophageal junction adenocarcinoma: In a phase I trial (ACE-Gastric-01), the novel ADC drug ARX788 exhibited good tolerability and antitumor activity in treating patients with HER2-positive advanced gastric cancer and GEJ adenocarcinoma [91].